New Zealand markets open in 7 hours 50 minutes

Aridis Pharmaceuticals, Inc. (ARDS)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0574-0.0046 (-7.42%)
At close: 03:32PM EDT

Aridis Pharmaceuticals, Inc.

983 University Avenue
Building B
Los Gatos, CA 95032
United States
408 385 1742
https://www.aridispharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees37

Key executives

NameTitlePayExercisedYear born
Dr. Eric J. Patzer Ph.D.Founder & Executive Chairman240kN/A1949
Dr. Vu L. Truong Ph.D.Founder, CEO, Chief Scientific Officer & Director631.65kN/A1964
Dr. Hasan Jafri M.D.Chief Medical Officer559.36kN/A1967
Ms. Tamara S. AllenVice President of FinanceN/AN/A1967
Mr. Jeffrey J. Fessler Esq., J.D.Acting General CounselN/AN/A1963
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Corporate governance

Aridis Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.